Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.50
Bid: 1,756.50
Ask: 1,757.00
Change: 26.50 (1.53%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,759.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Ignoring WHO call, major nations stick to vaccine booster plans

Thu, 05th Aug 2021 09:09

* Global body disapproves of boosters until more people
vaccinated

* Some rich nations going ahead anyway to fend off Delta
variant

* Elderly and vulnerable to benefit first from booster shots

* Low-income nations suffer from lack of vaccine supplies
(Adds more remarks from Israeli PM, paras 7-8)

By Sudip Kar-Gupta and Caroline Copley

PARIS/BERLIN, Aug 5 (Reuters) - Germany, France and Israel
will go ahead with plans to administer COVID-19 vaccine
boosters, disregarding an appeal by the World Health
Organisation to hold off until more people are vaccinated around
the world.

The decision to press ahead with booster shots despite the
WHO's strongest statement yet highlights the huge inequities in
responses to the pandemic as richer nations ramp up programmes
to protect citizens from the more infectious Delta variant.

French President Emmanuel Macron said France was working on
rolling out third doses to the elderly and vulnerable from
September.

Germany intends to give boosters to immunocompromised
patients, the very elderly and nursing home residents from
September, the health ministry said.

Israeli Prime Minister Naftali Bennett in a statement urged
older citizens to get a third shot after the government last
month kicked off a campaign to give booster doses.

"Whoever is over the age of 60, and has yet to receive the
third dose of the vaccine, is six times more susceptible to
severe illness and - heaven forbid - death," Bennett said.

In an online discussion with the public and journalists,
Bennett said Israel's drive to give third doses of the
Pfizer/BioNTech vaccine to people over 60 would provide vital
information to the world on combating the Delta variant.

Israel, with a population of 9.3 million, was a small
country whose vaccine use "doesn't really affect the world
supply significantly", he added.

WHO chief Tedros Adhanom Ghebreyesus called on Wednesday for
a halt to boosters until at least the end of September, saying
it was unacceptable for rich countries to use more of the global
vaccine supply.

INEQUALITIES MOUNT

High-income countries administered around 50 doses for every
100 people in May, and that number has since doubled, according
to WHO. Low-income countries have only been able to administer
1.5 doses for every 100 people, due to lack of supplies.

"I understand the concern of all governments to protect
their people from the Delta variant. But we cannot accept
countries that have already used most of the global supply of
vaccines using even more of it," Tedros said.

Germany rejected those accusations, saying it would also
donate at least 30 million vaccine doses to poorer countries.

"We want to provide the vulnerable groups in Germany with a
precautionary third vaccination and at the same time support the
vaccination of as many people in the world as possible," the
health ministry said.

Following Tedros' comments, the White House said on
Wednesday it was prepared to provide booster shots if needed,
suggesting it would not heed the WHO's call either.

Pfizer has said boosters are most likely needed due
to waning antibody responses, particularly after six months.

U.S. health regulators have said that more scientific
evidence is needed to be certain boosters are needed, but have
indicated they believe a third shot may be needed for people
with compromised immune systems.

Macron's government is trying to step up France's
vaccination programme as the country faces a fourth wave of the
virus and street demonstrations in protest against the
government's COVID policies.

France and Germany have so far given at least one dose of a
COVID-19 vaccine to 64.5% and 62% of their respective
populations, with 49% of the French and 53% of Germans fully
vaccinated.

(Reporting by Sudip Kar-Gupta and Nicolas Delame in Paris,
Alexander Ratz and Caroline Copley in Berlin, Jeffrey Heller in
Jerusalem; Editing by Nick Macfie, Josephine Mason, Andrew
Cawthorne, William Maclean)

More News
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
24 May 2024 15:19

London close: Stocks mixed after disappointing retail sales data

(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted to a larger-than-expected drop in UK retail sales.

Read more
24 May 2024 08:55

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April

(Alliance News) - Stock prices in London opened lower on Friday, with sentiment hurt across the globe.

Read more
24 May 2024 08:36

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case

(Alliance News) - GSK PLC on Friday welcomed the jury verdict in the Valadez case in Illinois state court, which found in GSK's favour in the first Zantac case to go to trial.

Read more
24 May 2024 07:52

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal

(Alliance News) - Stocks are called to open lower on Friday, following New York lower, as hopes of interest rate cuts have come into question.

Read more
24 May 2024 07:30

Jury rules in favour of GSK in Zantac trial

(Sharecast News) - A court in Illinois has ruled in favour of GSK in the first Zantac case to go to trial, the UK drugs giant confirmed on Friday.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 08:49

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.

Read more
21 May 2024 07:21

GSK reports promising results from asthma treatment trials

(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.

Read more
20 May 2024 16:11

IN BRIEF: GSK executive buys GBP20,026 worth shares

GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares at 1,788 pence each. Worth total GBP20,026.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.